Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
Autor: | Hironaga Satake, Nobuhiro Shibata, Mototsugu Shimokawa, T. Ikoma, Hiroki Nagai, Shogen Boku, Hisateru Yasui, Toshihiko Matsumoto, Masahito Kotaka |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
0301 basic medicine Neuroblastoma RAS viral oncogene homolog Oncology Cancer Research endocrine system diseases Colorectal cancer Mutant medicine.disease_cause GTP Phosphohydrolases 0302 clinical medicine Surgical oncology Medicine RC254-282 Aged 80 and over Hazard ratio Neoplasms. Tumors. Oncology. Including cancer and carcinogens Middle Aged Prognosis 030220 oncology & carcinogenesis Female KRAS KRAS non-Exon2 Colorectal Neoplasms Adult Proto-Oncogene Proteins B-raf medicine.medical_specialty Adolescent NRAS Proto-Oncogene Proteins p21(ras) Young Adult 03 medical and health sciences Internal medicine Genetics Overall survival Humans neoplasms KRAS Exon2 Aged business.industry Research Membrane Proteins medicine.disease digestive system diseases 030104 developmental biology Multicenter study Mutation business |
Zdroj: | BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background RAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant metastatic CRC (mCRC) in Japan. Methods A total of 152 chemotherapy-naïve patients with mCRC were included in this study between August 2018 and July 2019. Tumor samples were collected, and RAS/BRAFV600E status was investigated. RAS/BRAFV600E status was examined using a MEBGEN RASKET-B kit and polymerase chain reaction reverse sequence-specific oligonucleotide method. Results RAS/BRAFV600E mutations were detected in 54% of cases (KRAS codon 12, 26%; KRAS codon 13, 17%; KRAS non-Exon2, 5%; NRAS, 5%; and BRAFV600E, 7%). BRAFV600E-mutant CRC mainly existed in the right colon, whereas KRAS non-Exon2 and NRAS-mutant CRC was predominantly present in the left colon. KRAS non-Exon2 and NRAS-mutant CRC were associated with shorter survival time than RAS wild-type CRC (hazard ratio [HR], 2.26; 95% confidence interval [CI], 0.64–8.03; p = 0.19; HR, 2.42; 95% CI, 0.68–8.61; p = 0.16) and significantly shorter overall survival than KRAS Exon2-mutant CRC (HR, 3.88; 95% CI, 0.92–16.3; p = 0.04; HR, 4.80; 95% CI, 1.14–20.2; p = 0.02). Conclusions In our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant mCRC in Japan. |
Databáze: | OpenAIRE |
Externí odkaz: |